Phase Ib/II trial data for trastuzumab-DM1 in combination with pertuzumab presented at ASCO 2010

Jun 7 2010

ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of clinical data from a Phase Ib/II trial conducted by Roche and Genentech to investigate the safety and preliminary efficacy of trastuzumab-DM1 (T-DM1) used in combination with Roche's investigational antibody, pertuzumab. The findings were reported at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago, IL (abstract #1012).

“The tolerability seen with TAP compounds when used as single agents supports assessing them as part of combination regimens”

The data reported provide further support for the tolerability profile of compounds made with ImmunoGen's Targeted Antibody Payload (TAP) technology. T-DM1 utilizes ImmunoGen's TAP technology and is in global development by Roche.

"The tolerability seen with TAP compounds when used as single agents supports assessing them as part of combination regimens," commented Daniel Junius, President and Chief Executive Officer. "In addition to assessment with pertuzumab, Roche has trials underway that assess - separately - T-DM1 in combination with two taxane compounds and another of its investigational agents, GDC-0941. Similarly, we're assessing our lorvotuzumab mertansine TAP compound in combination with lenalidomide and dexamethasone, and we plan to start a second combination trial with this product candidate later this year. There's been substantial growth in the number of clinical trials evaluating TAP compounds as single agents and in combination, and we expect this growth to continue to accelerate."

SOURCE ImmunoGen, Inc.